CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2006-04-26): HBV variant resistant to adefovir identified


HBV variant resistant to adefovir identified

Last Updated: 2006-04-26 17:00:39 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Researchers have identified a variant of hepatitis B virus (HBV) with primary resistance to the reverse transcriptase inhibitor adefovir (Hepsera), a commonly used back-up drug when resistance to lamivudine (Zeffix) develops.

In a report in the April 27th issue of The New England Journal of Medicine, Dr. Wolfram H. Gerlich, from the University of Giessen in Germany, and colleagues describe three patients with chronic hepatitis B who were infected with an HBV variant with primary adefovir resistance.

Instead of having isoleucine at position 233 of the reverse-transcriptase domain, as occurs in wild-type strains, the variant had valine. All three patients responded to treatment with tenofovir (Viread) and in vitro testing confirmed viral sensitivity to this agent.

"Our observations demonstrate that some naturally occurring HBV strains are primarily resistant to adefovir," the authors write. In addition, the mutation conferring resistance was independent of lamivudine resistance, they add.

N Engl J Med 2006;354:1807-1812.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.